Sugi Predict

Sugi Predict / Compounds / SCHEMBL14979723

SCHEMBL14979723

SCHEMBL14979723

CC(C)(C)OC(=O)N1CCC[C@H]1c1nc2c([nH]1)CCc1c-2ccc2c1OCc1cc(Cl)ccc1-2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 3/20 0.40
▸ LMNA P02545 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ ALDH1A1 P00352 3/20 0.37
▸ USP30 Q70CQ3 2/20 0.37
▸ POLB P06746 1/20 0.37
▸ PTGES O14684 2/20 0.36
▸ HCRTR1 O43613 4/20 0.35
▸ HCRTR2 O43614 4/20 0.35
▸ UCHL1 P09936 2/20 0.34
▸ EED O75530 1/20 0.34
▸ RBBP4 Q09028 1/20 0.34
▸ SUZ12 Q15022 1/20 0.34
▸ EZH2 Q15910 1/20 0.34
▸ AEBP2 Q6ZN18 1/20 0.34
▸ ROCK2 O75116 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6126204 0.90 HCRTR1 (0.35) HCRTR1HCRTR2ROCK2CYP3A4CYP2C9
SCHEMBL15072179 0.86 USP30 (0.35) TSHRLMNAMEN1MAPTHTT
SCHEMBL14979700 0.81 HCRTR1 (0.44) TSHRLMNAMEN1MAPTHTT
SCHEMBL8752289 0.80 TSHR (0.40) TSHRLMNAMEN1MAPTHTT
SCHEMBL6126763 0.80 TSHR (0.40) TSHRLMNAMEN1MAPTHTT
SCHEMBL15076855 0.79 CYP3A4 (0.56) CYP3A4CYP2C9
SCHEMBL15072187 0.79 CYP3A4 (0.56) CYP3A4CYP2C9
SCHEMBL15443646 0.79 CYP3A4 (0.56) CYP3A4CYP2C9
SCHEMBL15430410 0.79 CYP3A4 (0.56) CYP3A4CYP2C9
SCHEMBL10182372 0.78 CYP3A4 (0.40) TSHRLMNAMEN1MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210053981-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2021-02-25 — — US disclosed
EP-3778606-A2 CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS Gilead Pharmasset LLC (US) 2021-02-17 — — EP disclosed
US-10807990-B2 Antiviral compounds GILEAD PHARMASSET LLC (US) 2020-10-20 — — US disclosed
US-20200123132-A1 ANTIVIRAL COMPOUNDS GILEAD PHARMASSET LLC 2020-04-23 — — US disclosed
US-20200071337-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2020-03-05 — — US disclosed
US-20190276468-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2019-09-12 — — US disclosed
US-10344019-B2 Antiviral compounds GILEAD PHARMASSET LLC (US) 2019-07-09 — — US disclosed
EP-3431477-A1 CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS Gilead Pharmasset LLC (US) 2019-01-23 — — EP disclosed
US-20180186806-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2018-07-05 — — US disclosed
US-20180186806-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2018-07-05 — — US disclosed
US-8575135-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2013-11-05 — — US disclosed
US-8575135-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2013-11-05 — — US disclosed
US-20130177530-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2013-07-11 — — US disclosed
US-20130177530-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2013-07-11 — — US disclosed
US-20130164260-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2013-06-27 — — US disclosed
US-20130164260-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2013-06-27 — — US disclosed
US-20130164260-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2013-06-27 — — US disclosed
US-20130156732-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2013-06-20 — — US disclosed
US-20130156732-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2013-06-20 — — US disclosed
WO-2013075029-A1 CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2013-05-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130177530-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, SARS1 TSHR 4860/4885LMNA 1463/4885MEN1 4581/4885
US-20200071337-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, SARS1 TSHR 4860/4885LMNA 1463/4885MEN1 4581/4885
US-20180186806-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, SARS1 TSHR 4860/4885LMNA 1463/4885MEN1 4581/4885
US-10344019-B2 Antiviral compounds MAVS, EIF2AK2, ZC3HAV1 TSHR 4853/4885LMNA 1353/4885MEN1 4292/4885
US-20130156732-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, SARS1 TSHR 4860/4885LMNA 1463/4885MEN1 4581/4885
US-20190276468-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, SARS1 TSHR 4860/4885LMNA 1463/4885MEN1 4581/4885
US-10807990-B2 Antiviral compounds MAVS, EIF2AK2, SARS1 TSHR 4860/4885LMNA 1463/4885MEN1 4581/4885
US-20130164260-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, SARS1 TSHR 4860/4885LMNA 1463/4885MEN1 4581/4885
US-20200123132-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 TSHR 4853/4885LMNA 1353/4885MEN1 4292/4885
US-20210053981-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, SARS1 TSHR 4860/4885LMNA 1463/4885MEN1 4581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.